{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:26:36Z","timestamp":1793042796641,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bioorg.2025.108709","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:50:30Z","timestamp":1751025030000},"page":"108709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A comprehensive review on the role of nitrogen containing heterocycles in overcoming ABC transporter mediated multidrug resistance in cancer"],"prefix":"10.1016","volume":"163","author":[{"given":"Anwesh","family":"Naik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Juvale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108709_bb0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin. Med. J."},{"issue":"2024","key":"10.1016\/j.bioorg.2025.108709_bb0010","first-page":"229","article-title":"GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.108709_bb0015","series-title":"Recent Advances in Cancer Therapy: An Overview","author":"Urruticoechea","year":"2024"},{"key":"10.1016\/j.bioorg.2025.108709_bb0020","article-title":"Successes and limitations of targeted Cancer therapy in breast","author":"Curigliano","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.108709_bb0025","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/molecules27030616","article-title":"Multidrug resistance (MDR): a widespread phenomenon in Pharmacological therapies","volume":"27","author":"Catalano","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108709_bb0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","article-title":"Biochemical, cellular, and PHARMACOLOGICAL aspects of the multidrug TRANSPORTER1","volume":"39","author":"Ambudkar","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108709_bb0035","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bmcl.2003.12.015","article-title":"Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates","volume":"14","author":"Zloh","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108709_bb0040","first-page":"99","article-title":"Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer","volume":"4","author":"Miele","year":"2009","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioorg.2025.108709_bb0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10915810600746023","article-title":"Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters","volume":"25","author":"Choudhuri","year":"2006","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108709_bb0050","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ppl.13302","article-title":"Role of ATP-binding cassette transporters in maintaining plant homeostasis under abiotic and biotic stresses","volume":"171","author":"Dahuja","year":"2021","journal-title":"Physiol. Plant."},{"key":"10.1016\/j.bioorg.2025.108709_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11171","article-title":"P-glycoprotein and cancer: what do we currently know","volume":"8","author":"Pilotto Heming","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2025.108709_bb0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/17425255.2021.1887139","article-title":"The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer","volume":"17","author":"Wang","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108709_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.22159\/ijpps.2023v15i6.47362","article-title":"Development of organometallic compounds of schiff bases with diverse applications","author":"Dinnimath","year":"2023","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.bioorg.2025.108709_bb0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1186\/s12935-021-02202-5","article-title":"Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs","volume":"21","author":"Olatunde","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioorg.2025.108709_bb0075","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00262-021-03013-3","article-title":"Chemotherapy: a double-edged sword in cancer treatment","volume":"71","author":"Nafiseh","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bioorg.2025.108709_bb0080","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","article-title":"Persistent Cancer cells: the deadly survivors","volume":"183","author":"Shen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108709_bb0085","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.3390\/ijms22094673","article-title":"Drug resistance in metastatic breast Cancer: tumor targeted nanomedicine to the rescue","volume":"22","author":"Gote","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108709_bb0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41574-022-00745-9","article-title":"The ATP-binding cassette proteins ABCB1 and ABCC1 as modulators of glucocorticoid action","volume":"19","author":"Devine","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108709_bb0095","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.3390\/ijms22073742","article-title":"Disease-Induced Modulation of Drug Transporters at the Blood\u2013Brain Barrier Level","volume":"22","author":"Al Rihani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108709_bb0100","unstructured":"K. Juvale, Development of New Breast Cancer Resistance Protein Inhibitors, Thesis, Universit\u00e4ts- und Landesbibliothek Bonn, 2013. https:\/\/bonndoc.ulb.uni-bonn.de\/xmlui\/handle\/20.500.11811\/5711 (accessed May 23, 2024)."},{"key":"10.1016\/j.bioorg.2025.108709_bb0105","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1124\/dmd.108.024489","article-title":"The effect of breast Cancer resistance protein and P-glycoprotein on the brain penetration of Flavopiridol, Imatinib Mesylate (Gleevec), prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice","volume":"37","author":"Zhou","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bioorg.2025.108709_bb0110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/mol.64.3.610","article-title":"Breast Cancer resistance protein exports sulfated estrogens but not free estrogens","volume":"64","author":"Imai","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"Pt 11","key":"10.1016\/j.bioorg.2025.108709_bb0115","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1242\/jcs.113.11.2011","article-title":"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)","volume":"113","author":"Litman","year":"2000","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bioorg.2025.108709_bb0120","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V99.2.507","article-title":"The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors","volume":"99","author":"Scharenberg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108709_bb0125","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108709_bb0130","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/15216540701736285","article-title":"Role of the MRP1\/ABCC1 multidrug transporter protein in Cancer","volume":"59","author":"Munoz","year":"2007","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bioorg.2025.108709_bb0135","series-title":"Molecular Mechanisms of Phase II Metabolizing Enzymes and ABC Transporters, and their Interactions with Small Molecules Modeled through Structure-Based and Machine Learning Methods, Phdthesis","author":"Dudas","year":"2022"},{"key":"10.1016\/j.bioorg.2025.108709_bb0140","unstructured":"J. Kyeremateng, Characterization of Cucurbitacin-inspired Estrone analogues as novel inhibitors of human ATP- binding cassetteProteins (ABCB1 and ABCC1), South Dakota State University, 2021. https:\/\/openprairie.sdstate.edu\/etd\/5212 (accessed March 10, 2025)."},{"key":"10.1016\/j.bioorg.2025.108709_bb0145","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220012120","article-title":"A macrocyclic peptide inhibitor traps MRP1 in a catalytically incompetent conformation","volume":"120","author":"Pietz","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108709_bb0150","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1124\/dmd.109.027193","article-title":"Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1\/multidrug resistance-associated protein (MRP) 2\/MRP3 and OATP1B1\/MRP2\/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4","volume":"37","author":"Hirouchi","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bioorg.2025.108709_bb0155","unstructured":"V.O. Poku, Identification and Characterization of Modulators of Human MRP1 (ABCC1) and Human MRP2 (ABCC2) Expression, South Dakota State University, 2021. https:\/\/openprairie.sdstate.edu\/etd\/5203 (accessed March 10,2025)."},{"key":"10.1016\/j.bioorg.2025.108709_bb0160","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1016\/j.arabjc.2016.10.009","article-title":"Comprehensive review on current developments of quinoline-based anticancer agents","volume":"12","author":"Jain","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0165","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/cmdc.202100188","article-title":"Tetrahydroquinoline\/4,5-Dihydroisoxazole molecular hybrids as inhibitors of breast Cancer resistance protein (BCRP\/ABCG2)","volume":"16","author":"Vesga","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.108709_bb0170","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bmc.2014.11.043","article-title":"IND-2, a pyrimido[1\u2033,2\u2033,1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells","volume":"23","author":"Karthikeyan","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canlet.2016.03.030","article-title":"Pyrimido[1\u2033,2\u2033,1,5]pyrazolo[3,4-b]quinolines: novel compounds that reverse ABCG2-mediated resistance in cancer cells","volume":"376","author":"Karthikeyan","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108709_bb0180","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1021\/jm8013822","article-title":"Potent and selective inhibitors of breast Cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator Tariquidar","volume":"52","author":"K\u00fchnle","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0185","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/ml4000832","article-title":"Benzanilide\u2013Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators","volume":"4","author":"Ochoa-Puentes","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108709_bb0190","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \u201cspecific\u201d P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast Cancer resistance protein (BCRP\/ABCG2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108709_bb0195","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ejmech.2015.06.049","article-title":"Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives","volume":"101","author":"Li","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0200","article-title":"New analogs of Tariquidar: synthesis, characterization and evaluation of their inhibitory activity against breast Cancer resistance protein (ABCG2)","author":"Pe\u00f1a Sol\u00f3rzano","year":"2018","journal-title":"phd"},{"key":"10.1016\/j.bioorg.2025.108709_bb0205","series-title":"Stud. Nat. Prod. Chem","first-page":"185","article-title":"Chapter 7 - Importance of quinazoline and quinazolinone derivatives in medicinal chemistry","author":"Bhat","year":"2021"},{"key":"10.1016\/j.bioorg.2025.108709_bb0210","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejmech.2018.10.026","article-title":"Synthesis and biological evaluation of quinazoline derivatives \u2013 a SAR study of novel inhibitors of ABCG2","volume":"161","author":"Krapf","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0215","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/biom13020253","article-title":"Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability","volume":"13","author":"Chao-Yun","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2025.108709_bb0220","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejmech.2016.03.067","article-title":"The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP\/ABCG2)","volume":"117","author":"Kraege","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0225","doi-asserted-by":"crossref","first-page":"7858","DOI":"10.1016\/j.bmc.2013.10.007","article-title":"Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)","volume":"21","author":"Juvale","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0230","doi-asserted-by":"crossref","first-page":"7952","DOI":"10.1021\/acs.jmedchem.8b01011","article-title":"2,4,6-substituted Quinazolines with extraordinary inhibitory potency toward ABCG2","volume":"61","author":"Krapf","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0235","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/pharmaceutics15010241","article-title":"The more the better\u2014investigation of Polymethoxylated N-Carboranyl Quinazolines as novel hybrid breast Cancer resistance protein inhibitors","volume":"15","author":"Stockmann","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.108709_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200027","article-title":"Overcoming multidrug resistance (MDR): design, biological evaluation and molecular modelling studies of 2,4-substituted Quinazoline derivatives","volume":"17","author":"Braconi","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.108709_bb0245","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cmdc.201100543","article-title":"Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K\/Akt signaling pathway","volume":"7","author":"Pick","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.108709_bb0250","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1016\/j.bmcl.2012.08.024","article-title":"4-Substituted-2-phenylquinazolines as inhibitors of BCRP","volume":"22","author":"Juvale","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108709_bb0255","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.2147\/DDDT.S307113","article-title":"Imidazole as a Promising Medicinal Scaffold: Current Status and Future Direction","volume":"15","author":"Alghamdi","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bioorg.2025.108709_bb0260","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1039\/C7MD00067G","article-title":"Imidazoles as potential anticancer agents \u2020the authors declare no competing interests","volume":"8","author":"Ali","year":"2017","journal-title":"MedChemComm"},{"key":"10.1016\/j.bioorg.2025.108709_bb0265","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1080\/14756366.2022.2127700","article-title":"Molecular design, synthesis and biological evaluation of novel 1,2,5-trisubstituted benzimidazole derivatives as cytotoxic agents endowed with ABCB1 inhibitory action to overcome multidrug resistance in cancer cells","volume":"37","author":"Abdelhafiz","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0270","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1021\/acsmedchemlett.6b00046","article-title":"Ferrocenyl 2,5-Piperazinediones as tubulin-binding organometallic ABCB 1 and ABCG 2 inhibitors active against MDR cells","volume":"7","author":"Wieczorek","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108709_bb0275","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2018.10.007","article-title":"Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells","volume":"440\u2013441","author":"Ji","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108709_bb0280","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.1039\/c1cc10685f","article-title":"Triazole: a unique building block for the construction of functional materials","volume":"47","author":"Jur\u00ed\u010dek","year":"2011","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bioorg.2025.108709_bb0285","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1016\/S1452-3981(23)13954-X","article-title":"Corrosion inhibition of copper in non-polluted and Polluted Sea water using 5-phenyl-1-H-tetrazole","volume":"7","author":"Al Kharafi","year":"2012","journal-title":"Int. J. Electrochem. Sci."},{"key":"10.1016\/j.bioorg.2025.108709_bb0290","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ejmech.2018.01.012","article-title":"Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors","volume":"146","author":"K\u00f6hler","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0295","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1021\/acs.jmedchem.9b00963","article-title":"Triazole bridged flavonoid dimers as potent, nontoxic, and highly selective breast Cancer resistance protein (BCRP\/ABCG2) inhibitors","volume":"62","author":"Zhu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0300","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1016\/j.bmcl.2017.09.009","article-title":"Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors","volume":"27","author":"Gujarati","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108709_bb0305","series-title":"Discovery of ABCG2\/VEGFR2 Dual-Target Inhibitor With Anti-Drug Resistance Activity Based on the ATP Binding Site","author":"Liang","year":"2020"},{"key":"10.1016\/j.bioorg.2025.108709_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112458","article-title":"Pyrimidine: a promising scaffold for optimization to develop the inhibitors of ABC transporters","volume":"200","author":"He","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0315","doi-asserted-by":"crossref","first-page":"15979","DOI":"10.1021\/acs.jmedchem.0c01741","article-title":"Structure-based design, synthesis, and biological evaluation of new Triazolo[1,5-a]pyrimidine derivatives as highly potent and orally active ABCB1 modulators","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172611","article-title":"Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance","volume":"863","author":"Wang","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108709_bb0325","doi-asserted-by":"crossref","first-page":"10412","DOI":"10.1021\/acs.jmedchem.0c00961","article-title":"Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists","volume":"63","author":"Silbermann","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105326","article-title":"Lhassane Ismaili, synthesis and biological assessment of new pyrimidopyrimidines as inhibitors of breast cancer resistance protein (ABCG2)","volume":"116","author":"Dakhlaoui","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113403","article-title":"Discovery of new pyrimidopyrrolizine\/indolizine-based derivatives as P-glycoprotein inhibitors: design, synthesis, cytotoxicity, and MDR reversal activities","volume":"218","author":"Shawky","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0340","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1021\/acs.jmedchem.5b01644","article-title":"Pyrrolopyrimidine derivatives as novel inhibitors of multidrug resistance-associated protein 1 (MRP1, ABCC1)","volume":"59","author":"Schmitt","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112359","article-title":"Current scenario of indole derivatives with potential anti-drug-resistant cancer activity","volume":"200","author":"Jia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0350","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41598-020-79892-w","article-title":"Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles","volume":"11","author":"Kita","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108709_bb0355","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1021\/jm401649j","article-title":"Structure\u2013Activity Relationships of Chromone Derivatives toward the Mechanism of Interaction with and Inhibition of Breast Cancer Resistance Protein ABCG2","volume":"56","author":"Winter","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0360","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acs.jmedchem.2c01612","article-title":"Indole derivatives as new structural class of potent and Antiproliferative inhibitors of Monocarboxylate transporter 1 (MCT1; SLC16A1)","volume":"66","author":"Puri","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0365","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.3390\/cancers12113249","article-title":"Poziotinib inhibits the efflux activity of the ABCB1 and ABCG2 transporters and the expression of the ABCG2 transporter protein in multidrug resistant Colon Cancer cells","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.108709_bb0370","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1038\/emm.2016.168","article-title":"Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo","volume":"49","author":"Yang","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108709_bb0375","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1021\/acs.jmedchem.6b00035","article-title":"Synthesis and investigation of Tetrahydro-\u03b2-carboline derivatives as inhibitors of the breast Cancer resistance protein (ABCG2)","volume":"59","author":"Spindler","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115716","article-title":"Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and elacridar: new potent P-gp modulators acting as MDR reversers","volume":"259","author":"Braconi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103492","article-title":"Design, molecular modeling and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as inhibitors of topoisomerase II","volume":"94","author":"El-Metwally","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0390","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00280-015-2858-9","article-title":"Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors","volume":"76","author":"Darby","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108709_bb0395","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V100.5.1910.h81702001910_1910_1912","article-title":"Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase","volume":"100","author":"List","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108709_bb0400","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1021\/acs.accounts.8b00570","article-title":"Allosteric methods and their Applications: facilitating the discovery of allosteric drugs and the investigation of allosteric mechanisms","volume":"52","author":"Lu","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bioorg.2025.108709_bb0405","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1021\/acs.jmedchem.3c00283","article-title":"Discovery of Pyxinol amide derivatives bearing amino acid residues as nonsubstrate allosteric inhibitors of P-glycoprotein-mediated multidrug resistance","volume":"66","author":"Yang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108709_bb0410","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108709_bb0415","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.2174\/1381612828666220401142300","article-title":"Applications of nanotechnology-based approaches to overcome multi-drug resistance in Cancer","volume":"28","author":"Kalave","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioorg.2025.108709_bb0420","doi-asserted-by":"crossref","first-page":"390","DOI":"10.20517\/cdr.2023.16","article-title":"Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system","volume":"6","author":"Sun","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bioorg.2025.108709_bb0425","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.xphs.2016.05.012","article-title":"Usefulness of transporter-targeted prodrugs in enhancing membrane permeability","volume":"105","author":"Murakami","year":"2016","journal-title":"J. Pharm. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825005899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825005899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:10:54Z","timestamp":1776921054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825005899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":85,"alternative-id":["S0045206825005899"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108709","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review on the role of nitrogen containing heterocycles in overcoming ABC transporter mediated multidrug resistance in cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108709"}}